Exenatide: Difference between revisions

| onset = Glycemic effect within hours (Byetta); weeks (Bydureon — extended-release microsphere)<ref name="bydureon-label"/>

| halflife = ~2.4 hours (Byetta — short, hence the BID schedule)<ref name="byetta-label"/> · Effective release half-life ~2 weeks (Bydureon)<ref name="bydureon-label"/>

Exenatide is a synthetic version of '''exendin-4''', originally isolated by John Eng at the Bronx VA Medical Center in 1992 from the saliva of the [[Gila monster]] (''[[Heloderma suspectum]]'').<ref name="eng1992"/> The peptide is only 53% homologous to native human GLP-1 but is naturally resistant to DPP-4 — that natural resistance is what made it the first clinically usable incretin mimetic, validating the GLP-1 receptor as a therapeutic target and opening the path to all subsequent agents in the class.

In contrast to the long-acting weekly agents that followed, exenatide carries a heavier GI side-effect burden (especially Byetta BID) and is associated with anti-exenatide antibody formation in a substantial minority of users — antibodies that can reduce efficacy.<ref name="byetta-label"/> Twice-daily Byetta was discontinued in the United States in 2024.{{Citation needed}} Bydureon BCise remains available but is no longer commonly prescribed first-line.

| pharmacokinetics = '''Chemistry'''. '''Exendin-4''' — a 39-amino-acid peptide originally isolated from the saliva of the Gila monster (''[[Heloderma suspectum]]''). Only 53% homologous with human [[GLP-1]] but naturally resistant to [[DPP-4]] cleavage because of a glycine at position 2.<ref name="eng1992">Eng J, Kleinman WA, Singh L et al. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from ''Heloderma suspectum'' venom. ''J Biol Chem'' 267(11):7402–5.</ref>

'''Bydureon BCise''' (weekly): exenatide is encapsulated in slow-release biodegradable polymer microspheres; multiple peaks occur as successive microsphere cohorts release the peptide. Steady-state plasma levels are reached only after 6–7 weeks of weekly dosing — meaning early efficacy looks weaker than other weekly GLP-1 RAs.<ref name="bydureon-label"/>

* Cardiovascular outcomes: '''non-inferior''' but not superior to placebo in T2DM (EXSCEL) — the only major GLP-1 RA CVOT not to demonstrate superiority<ref name="exscel">Holman RR, Bethel MA, Mentz RJ et al. (2017). Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL). ''NEJM'' 377(13):1228–39. doi:10.1056/NEJMoa1612917</ref>

| dosing = <titration slug="byetta-standard" author="MDElliottMD" title="Byetta — standard T2DM titration">

<titration slug="bydureon-standard" author="MDElliottMD" title="Bydureon BCise — standard T2DM dosing">

Steady-state plasma exenatide is reached only after 6–7 weeks of dosing — counsel patients that the medicine will keep ramping up well after the first injection. HbA1c response should be assessed at 12+ weeks, not earlier.<ref name="bydureon-label"/>

| effects = * '''Nausea''' — historically the highest of any GLP-1 RA. ~40–50% of Byetta BID users report nausea; ~20% with Bydureon weekly.<ref name="byetta-label"/><ref name="bydureon-label"/>

* '''Injection-site reactions''' — notably higher with Bydureon (small nodules at injection sites are common, often visible/palpable for weeks)<ref name="bydureon-label"/>

* '''Anti-exenatide antibodies''' — form in ~40% of users; high titers correlate with reduced glycemic efficacy<ref name="byetta-label"/>

| monitoring = * Baseline: HbA1c, weight, BP, renal function (especially important for exenatide — renally cleared)<ref name="byetta-label"/>

* Personal or family history of MTC or [[MEN2]] — '''contraindicated''', do not start (Bydureon only — Byetta's label predates the class boxed warning conversion)<ref name="bydureon-label"/>

* '''Pre-procedure''': Byetta — skip the dose before the procedure; Bydureon — hold weekly dose ≥7 days pre-op<ref name="kindel2024">Kindel TL et al. (2024). Perioperative GLP-1 receptor agonist safety guidance. ''Surg Obes Relat Dis'' 20(12):1183–8.</ref>

* Bydureon: same day each week. Suspension must be activated by vigorous shaking until uniformly cloudy — administration immediately after mixing is required.<ref name="bydureon-label"/>

* Expect small injection-site nodules with Bydureon — these are the polymer microspheres and usually resolve over weeks to months.<ref name="bydureon-label"/>